A comprehensive approach targeting blood pressure (BP), low-density lipoprotein cholesterol (LDLc), and hyperglycaemia is crucial in patients with type 2 diabetes (T2DM) [1]. There is a significant gap between the targets proposed by clinical practice guidelines (CPG) and their achievement in real-world practice. In a recent European study, 80%, 52.5%, and 37.4% of T2DM patients had a poor control of BP, LDLc, and HbA1c, respectively [2]. The proportion of patients who achieve a multifactorial control is even lower (5–10%) [2,3].
